KB-1173

Vorsetuzumab

Background

CD70 is a type II transmembrane protein, which is mainly expressed in activated T cells, B cells, natural killer (NK) cells, and dendritic cells. Vorsetuzumab is a monoclonal antibody targeting CD70 and can kill tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC). In addition, vorsetuzumab can also be conjugated with small molecular antitumor drugs to form a new type of targeted therapeutic molecules with accurate targeting and greater lethality.

Specifications

Catalog Number:
KB-1173
Cell Line Name:
Vorsetuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD70
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Jacobs, J.; Deschoolmeester, V.; Zwaenepoel, K.; Rolfo, C.; Silence, K.; Rottey, S.; Lardon, F.; Smits, E.; Pauwels, P. (2015). CD70: An emerging target in cancer immunotherapy. Pharmacology & Therapeutics, S016372581500145X.  2.Jin, Linchun; Ge, Haitao; Long, Yu; Yang, Changlin; Chang, Yifan (Emily); Mu, Luyan; Sayour, Elias J.; De Leon, Gabriel; Wang, Qiong J.; Yang, James C.; Kubilis, Paul S.; Bao, Hongbo; Xia, Songsong; Lu, Dunyue; Kong, Yingjun; Hu, Li; Shang, Yujiao; Jiang, Chencheng; Nie, Jing; Li, Shimin; Gu, Yunhe; Sun, Jiahang; Mitchell, Duane A.; Lin, Zhiguo; Huang, Jianping (2017). CD70, a novel target of CAR-T-cell therapy for gliomas. Neuro-Oncology.
Please enable JavaScript in your browser to complete this form.